EMEA-001207-PIP01-11-M01

Table of contents

Key facts

Invented name
Gazyvaro
Active substance
Obinutuzumab
Therapeutic area
Oncology
Decision number
P/0196/2021
PIP number
EMEA-001207-PIP01-11-M01
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
  • Treatment of acute lymphoblastic leukaemia
  • Treatment of mature B-cell lymphoma
Route(s) of administration
Intravenous use
Contact for public enquiries
Roche Registration GmbH

E-mail: info.paediatrics@roche.com
Tel. +41 616879411

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating